• Ascletis flagged a wider loss attributable to equity shareholders of about RMB 319.7 million for the six months ended June 30, 2026.
• Compares with a loss of about RMB 88 million a year earlier, an increase of about 263.5%.
• R&D expenses seen rising about 132.7% to roughly RMB 341.7 million from about RMB 146.8 million, driven by metabolic pipeline investment.
• Cash and equivalents, time deposits, CDs, structured deposits, wealth products totaled about RMB 2.31 billion at June 30, 2026.
• Liquidity expected to fund operations into 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294750), on August 21, 2026, and is solely responsible for the information contained therein.